<div id="readability-page-1"><p>Meadowbrook Wealth Management LLC bought a new stake in  Abbott Laboratories (NYSE:ABT - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,270 shares of the healthcare product maker's stock, valued at approximately $1,242,000. Abbott Laboratories comprises approximately  1.3% of Meadowbrook Wealth Management LLC's investment portfolio, making the stock its 19th biggest position.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li></ul><p>Other hedge funds also recently modified their holdings of the company. IMG Wealth Management Inc. lifted its stake in shares of  Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock valued at $26,000 after buying an additional 167 shares during the period.  Anfield Capital Management LLC raised its holdings in  Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after acquiring an additional 104 shares during the last quarter.  Delos Wealth Advisors LLC acquired a new stake in shares of  Abbott Laboratories during the second quarter worth $32,000.  Curio Wealth LLC grew its position in shares of  Abbott Laboratories by 15,250.0% in the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares during the period.  Finally, Pineridge Advisors LLC lifted its position in  Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock worth $43,000 after buying an additional 81 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds. </p><h2>Abbott Laboratories Trading Up 0.3%</h2><p>NYSE:ABT opened at $125.45 on Friday. The business's 50-day moving average is $126.77 and its two-hundred day moving average is $130.27. The firm has a market capitalization of $218.13 billion, a PE ratio of 15.72, a price-to-earnings-growth ratio of 2.28 and a beta of 0.72. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. </p><ul><li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li></ul><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS.  Research analysts predict that  Abbott Laboratories will post 5.14 earnings per share for the current fiscal year. </p><h2>Abbott Laboratories Increases Dividend</h2><p>The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. Abbott Laboratories's dividend payout ratio  is presently 29.57%. </p><h2>Analyst Ratings Changes</h2><ul><li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li></ul><p>A number of research analysts have recently commented on ABT shares. Wells Fargo &amp; Company upped their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 16th. Weiss Ratings  restated a &#34;buy (b-)&#34; rating on shares of Abbott Laboratories in a report on Monday. Evercore ISI cut their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating on the stock in a research note on Wednesday, October 15th. Raymond James Financial boosted their price objective on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, October 16th. Finally, Royal Bank Of Canada  reiterated an &#34;outperform&#34; rating and issued a $147.00 target price on shares of Abbott Laboratories in a report on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned  a Buy rating and four have issued  a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p><p><b>Get Our Latest Stock Analysis on Abbott Laboratories</b></p><h2>Abbott Laboratories Profile</h2> (Free Report)<p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.  </p><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>What is a Dividend King? </li><li>MarketBeat Week in Review – 12/15 - 12/19</li><li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>Profitably Trade Stocks at 52-Week Highs</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Meadowbrook Wealth Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter, purchasing 9,270 shares valued at approximately $1,242,000. This investment represents 1.3% of Meadowbrook's portfolio. Abbott Laboratories' stock is held by 75.18% institutional investors and hedge funds. The company recently reported Q3 earnings of $1.30 per share and increased its quarterly dividend to $0.63 per share. Analysts have given positive ratings, with price targets ranging from $142 to $147.</p>

Meadowbrook Wealth Management LLC Acquires New Stake in Abbott Laboratories $ABT